Tolfenamic acid-induced alterations in genes and pathways in pancreatic cancer cells
Open Access
- 14 January 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (9) , 14593-14603
Abstract
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Umesh T. Sankpal1, Steve Goodison2, Michelle Jones-Pauley1, Myrna Hurtado3, Fan Zhang3, Riyaz Basha1, 3 1Texas College of Osteopathic Medicine, University of North Texas Health Science Center, TX, USA 2Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA 3Institute for Molecular Medicine, University of North Texas Health Science Center, TX, USA Correspondence to: Riyaz Basha, email: riyaz.basha@unthsc.edu Keywords: tolfenamic acid, pancreatic cancer, Sp1, microarray analysis Received: November 04, 2016 Accepted: January 05, 2017 Published: January 14, 2017 ABSTRACT Non-steroidal anti-inflammatory drugs (NSAIDs) are being tested extensively for their role in the treatment and prevention of several cancers. Typically NSAIDs exhibit anti-tumor activities via modulation of cyclooxygenase (COX)-dependent mechanisms, however, an anti-cancer NSAID tolfenamic acid (TA) is believed to work through COX-independent pathways. Results from our laboratory and others have demonstrated the anti-cancer activity of TA in various cancer models including pancreatic cancer. TA has been shown to modulate certain cellular processes including, apoptosis, reactive oxygen species and signaling. In this study, molecular profiling was performed to precisely understand the mode of action of TA. Three pancreatic cancer cell lines, L3.6pl, MIA PaCa-2, and Panc1 were treated with TA (50 μM for 48 h) and the changes in gene expression was evaluated using the Affymetrix GeneChip Human Gene ST Array platform. Microarray results were further validated using quantitative PCR for seven genes altered by TA treatment in all three cell lines. Functional analysis of differentially expressed genes (2 fold increase or decrease, p < 0.05) using Ingenuity Pathway Analysis software, revealed that TA treatment predominantly affected the genes involved in cell cycle, cell growth and proliferation, and cell death and survival. Promoter analysis of the differentially expressed genes revealed that they are enriched for Sp1 binding sites, suggesting that Sp1 could be a major contributor in mediating the effect of TA. The gene expression studies identified new targets involved in TA’s mode of action, while supporting the hypothesis about the association of Sp1 in TA mediated effects in pancreatic cancer.Keywords
This publication has 46 references indexed in Scilit:
- Small molecule tolfenamic acid and dietary spice curcumin treatment enhances antiproliferative effect in pancreatic cancer cells via suppressing Sp1, disrupting NF-kB translocation to nucleus and cell cycle phase distributionThe Journal of Nutritional Biochemistry, 2016
- Aspirin and colorectal cancer: the promise of precision chemopreventionNature Reviews Cancer, 2016
- p-21 activated kinase 4 promotes proliferation and survival of pancreatic cancer cells through AKT- and ERK-dependent activation of NF-κB pathwayOncotarget, 2014
- An Undesired Effect of ChemotherapyJournal of Biological Chemistry, 2013
- COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory DrugsFrontiers in Oncology, 2013
- Studies on Combination of Platinum Drugs Cisplatin and Oxaliplatin with Phytochemicals Anethole and Curcumin in Ovarian Tumour Models2012
- CXCL12/CXCR4 Protein Signaling Axis Induces Sonic Hedgehog Expression in Pancreatic Cancer Cells via Extracellular Regulated Kinase- and Akt Kinase-mediated Activation of Nuclear Factor κBJournal of Biological Chemistry, 2012
- Pancreatic CancerNew England Journal of Medicine, 2010
- Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case–control studyBritish Journal of Cancer, 2010
- Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenograftsCancer Biology & Therapy, 2004